Nilotinib hydrochloride anhydrous
-
Nilotinib hydrochloride anhydrous
structure -
-
CAS No:
923288-95-3
-
Formula:
C28H23ClF3N7O
-
Chemical Name:
Nilotinib hydrochloride anhydrous
-
Synonyms:
Nilotinib hydrochloride anhydrous;Nilotinib hydrochloride;4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}benzamide hydrochloride (1:1);AMN-107 HCl;Nilotinib hydrochloride anhydrou;Nilotinib hydrochloride anhydrous USP/EP/BP;Nilotinib HCI;Nilotinib hydrochloride, 10 mM in DMSO
-
CAS No:
Description
Nilotinib Hydrochloride Anhydrous is the hydrochloride salt of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.
Nilotinib hydrochloride anhydrous Basic Attributes
565.99
565.1604706
K37N7BYX3X
DTXSID60238968
C95223
Safety Information
|Danger|H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]|P201, P202, P260, P264, P273, P280, P281, P302+P352, P305+P351+P338, P308+P313, P314, P321, P332+P313, P337+P313, P362, P391, P405, and P501|Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Nilotinib hydrochloride anhydrous Use and Manufacturing
Nilotinib Hydrochloride might be useful in treatment of chronic myelogenous leukemia. It is a COVID19-related research product.
Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Recommended Suppliers of Nilotinib hydrochloride anhydrous
-
![China]()
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives
Learn More Other Chemicals
-
4H-1-Benzopyran-4-one, 2-[4-[3-(dibutylamino)propoxy]-3,5-dimethylbenzoyl]-, hydrochloride (1:1)
67652-33-9
-
Cyclopropanecarboxylic acid, 1-amino-2-ethenyl-, ethyl ester, hydrochloride (9CI)
681807-60-3
-
CYCLOPENTYL-(3,4,5-TRIMETHOXY-BENZYL)-AMINE HYDROCHLORIDE
1052525-88-8
-
2-Cyclopropylbenzenemethanamine hydrochloride Formula
118184-64-8
-
Des[4-(2-cycloproylMethoxy)] Betaxolol Hydrochloride Formula
464877-45-0
-
Ethanamine, 2-(decylthio)-, hydrochloride (1:1) Formula
36362-09-1
-
4,7-Dichloro-2-propylquinoline hydrochloride Structure
1204812-22-5
-
6,7-Dichloro-4-hydrazino-2-methylquinoline hydrochloride Structure
1170377-12-4
-
What is 2,8-Diazaspiro[4.5]decan-1-one, 2-[(4-bromophenyl)methyl]-, hydrochloride (1:1)
832710-56-2
-
What is 6,7-Dichloro-4-hydrazinoquinoline hydrochloride
1171843-02-9
Request for Quotation